Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Francisco Quintana
Brigham and Women's Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
AnTolRx, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The research project studies (1) how AHR expressed in dendritic cells (AHRDC) regulates autoimmune T‐cell response, and (2) its potential therapeutic target in multiple sclerosis. The company uses AHR to induce immune tolerance, and has an MS treatment in its development pipeline. It was determined that the results of this research (understanding the regulation of the autoimmune T‐cell response by AHRDC, and its potential as a therapeutic target) could affect the
financial interests of a company working on AHR in MS. Given the investigator’s private equity interest and cash compensation, it was determined that a conflict exists, as defined by the PHS regulations.
Role of AHR in Dendritic Cells in the Control of the CNS Autoimmunity
Autoimmune diseases are caused by the uncontrolled activity of the immune system. This project proposes to use in vitro and in vivo experimental systems to study the molecular mechanisms through which the aryl hydrocarbon receptor controls the immune response and to identify potential targets for therapeutic intervention in immune-mediated diseases.
Filed on March 07, 2017.
Tell us what you know about Francisco Quintana's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Francisco Quintana filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Francisco Quintana | Brigham and Women's Hospital | Conflict of Interest | AnTolRx, Inc. | $40,000 - $59,999 |
| Francisco Quintana | Brigham and Women's Hospital | Conflict of Interest | AnTolRx, Inc. | $40,000 - $59,999 |
| Francisco Quintana | Brigham and Women's Hospital | Conflict of Interest | AnTolRx, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.